Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1993-12-28
|
pubmed:abstractText |
The serological endpoint of response in the treatment of chronic hepatitis B is the loss of hepatitis B virus DNA and HBeAg. Because the quantitative measurement of hepatitis B virus DNA in serum has been shown to be useful for monitoring and predicting response to interferon-alpha therapy, we decided to evaluate whether changes in HBeAg concentration could also be used in this manner. Twenty-nine patients who were initially positive for HBeAg and HBV DNA were serially evaluated for HBeAg concentration with a microparticle-capture enzyme immunoassay. HBeAg levels in serum were calculated by means of comparison with a standard curve of fluorescence rate vs. HBeAg concentration. The results, expressed in milliunits per milliliter, were compared with hepatitis B virus DNA levels determined by means of solution hybridization. The baseline HBeAg concentration proved to be the best independent predictor of response on stepwise Cox regression analysis (p = 0.026). Similar disappearance curves were observed for the two markers, although hepatitis B virus DNA became undetectable at an earlier interval in 13 of 16 cases (81%). In the 16 responders, a decline in HBeAg concentration of more than 90% was observed by wk 12 of therapy (mean +/- S.D., 95% +/- 13%). Nonresponders did not demonstrate such steep declines in HBeAg values by wk 12 (mean +/- S.D., 45% +/- 27%), and levels tended to increase at subsequent time points. We conclude that serial monitoring of HBeAg concentration with a technique that should be readily adaptable to clinical laboratories may be useful in the initial evaluation and monitoring of patients undergoing antiviral therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B e Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0270-9139
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
18
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1306-12
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8244253-DNA, Viral,
pubmed-meshheading:8244253-Hepatitis Antibodies,
pubmed-meshheading:8244253-Hepatitis B,
pubmed-meshheading:8244253-Hepatitis B e Antigens,
pubmed-meshheading:8244253-Hepatitis B virus,
pubmed-meshheading:8244253-Humans,
pubmed-meshheading:8244253-Immunoenzyme Techniques,
pubmed-meshheading:8244253-Interferon-alpha,
pubmed-meshheading:8244253-Predictive Value of Tests,
pubmed-meshheading:8244253-Prognosis,
pubmed-meshheading:8244253-Recombinant Proteins,
pubmed-meshheading:8244253-Regression Analysis
|
pubmed:year |
1993
|
pubmed:articleTitle |
Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing.
|
pubmed:affiliation |
Department of Internal Medicine, St. Louis Veterans Affairs Medical Center, Missouri 63106.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|